Back

Prognostic impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy

30 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: diagnosis and outcomes Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Christina Maria Toferer

Graz (Austria)

7 More presentations in this session

Presentation thumbnail
Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis
Doctor V. Algalarrondo (Paris, FR)
Abstract Slides
Presentation thumbnail
Increased index of microcirculatory resistance, capillary rarefaction, elevated troponin levels, and their association with transthyretin amyloidosis cardiomyopathy
Mr Y. Suiko (Miyazaki, JP)
Abstract Slides
Presentation thumbnail
Association of cardiac amyloidosis with cardiovascular outcomes after aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis
Doctor T. Figueira (Stony Brook, US)
Abstract Slides
Presentation thumbnail
Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: diagnosis and outcomes

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2i effects depending on functional capacity in ATTR-CM
thumbnail
Congress Presentation
Impact of sodium-glucose cotransporter-2 inhibitors on survival in patients with cancer therapy-related cardiac dysfunction
thumbnail
Congress Presentation
SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources